Oncolytics Biotech (US:ONCY) Prnewswire·2025-06-11 11:00Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent with promising results in treating various cancers [6][7] - Pelareorep has received FDA Fast Track designation for metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) [3][6] Leadership Appointment - Jared Kelly has been appointed as the Chief Executive Officer and a member of the Board of Directors, bringing extensive experience in biotech and corporate strategy [1][2] - Kelly's previous role included orchestrating the $2 billion sale of Ambrx Biopharma to Johnson & Johnson, showcasing his expertise in transformative deals [2] Clinical Data and Development - Pelareorep has shown a greater than 60% objective response rate in mPDAC patients, significantly outperforming historical control trials [3] - In mBC, pelareorep demonstrated meaningful survival benefits in two randomized Phase 2 studies involving over 100 patients [4] - The agent has a favorable safety profile based on data from over 1,100 patients across multiple tumor types [4] Strategic Focus - The company aims to advance pelareorep through a renewed clinical development plan, targeting partnerships to enhance its market potential [3][4] - Oncolytics is conducting combination clinical trials with pelareorep in solid malignancies, moving towards registrational studies in mBC and pancreatic cancer [7] Incentives for Leadership - As part of his appointment, Kelly received stock options for 2,850,000 shares and performance-based options for 1,900,000 shares, aligning his incentives with shareholder value creation [5]